LONDON, Nov. 9, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/4985942
The report covers the number of patients for 10 cancer indications (i.e., Breast Cancer, Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Hodgkin's disease and Non-Hodgkin Lymphoma), who are at risk of developing CIN as an adverse event of the chemotherapies of respective cancers.
Neupogen (Filgrastim), developed and marketed by Amgen is the first G-CSF approved for chemotherapy-induced neutropenia (CIN) in 1991. Its PEGylated formulation, Neulasta was later approved in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute to majority of the market size, of CIN. However, New Chemical Entities are expected to launch in the near future. According to DelveInsight, the worldwide CIN market is estimated to increase at a CAGR of 3.37% for the forecast period i.e., 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Download the full report: https://www.reportbuyer.com/product/4985942
About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers https://www.reportbuyer.com
For more information:Sarah SmithResearch Advisor at Reportbuyer.comEmail: email@example.comTel: +44 208 816 85 48Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/chemotherapy-induced-neutropenia-cin--market-insights-epidemiology-and-market-forecast-2023-300553566.html
Subscribe to our Free Newsletters!
Our kitchen and food has the best medicinal properties to fight stress. These are the top 10 foods ...
Unripe green papaya fruit is a rich source of important nutrients including vitamins, proteins, & ...
Selfie obsession or selfitis, an obsessive, uncontrollable urge to post self-taken photographs on ...View All